期刊文献+

粗针穿刺多点检测法对于评估胃癌手术标本HER2基因表达状态的临床意义 被引量:4

原文传递
导出
摘要 目的探讨粗针穿刺多点检测法对于评估胃癌手术标本HER2基因表达状态的临床意义。方法选取河北医科大学第四医院外三科进展期胃癌手术患者50例,采用200mm直径全自动活检穿刺枪.对胃癌患者离体20min以内的大体标本进行快速、全层、多点(贲门侧、中心侧、幽门侧)取材.选10%中性缓冲甲醛液固定2—4h后送病理科进行HER2基因检测。利用荧光原位杂交(FISH)检测HER2蛋白为 的所有组织蜡块。将检测结果分别与胃镜咬检标本及胃癌手术后大体标本的常规HER2检测结果进行对比。结果多点粗针穿刺与胃镜咬检的HER2检测一致率为96%.与术后病理的HER2检测一致率为98%。其中1例术前咬检及术后传统标本检测HER2均为阴性,而3点穿刺结果为(-、 和 ),分别对HER2(廿)标区域进行FISH检测.其中心侧显示为FISH扩增阳性。结论多点粗针穿刺法与传统胃镜咬检及术后标本的HER2检测一致率较高,且具有快速、多点、全面等优点。
出处 《中华胃肠外科杂志》 CAS CSCD 北大核心 2017年第7期816-817,共2页 Chinese Journal of Gastrointestinal Surgery
基金 河北省科技计划项目任务书(17397706D)
  • 相关文献

参考文献4

二级参考文献27

  • 1汪斐,莫烨,周世权,陈森林,宁文锋,姚茂金,王永俊,施小六.COX-2和HER-2在结直肠癌中的表达及其意义[J].中国普通外科杂志,2007,16(7):693-695. 被引量:11
  • 2Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase Ilalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 2005, 16(2) :273-278.
  • 3Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008, 19 (9) : 1523-1529.
  • 4Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer, 2009, 100 ( 3 ) :487-493.
  • 5Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 ( HER2 )-positive advanced gastric cancer ( GC ). J Clin Oncol, 2009, 27 : 18S( suppl : abstr LBA4509 ).
  • 6Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742) :687-697.
  • 7Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52(7) :797-805.
  • 8Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe, 2010, 31 ( 3 ) :208-217.
  • 9RuschoffJ, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch, 2010, 457 ( 3 ) : 299-307.
  • 10Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol, 2011, In press.

共引文献135

同被引文献27

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部